Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Arlene B. Chapman, Olivier Devuyst, Kai Uwe Eckardt, Ron T. Gansevoort, Tess Harris, Shigeo Horie, Bertram L. Kasiske, Dwight Odland, York Pei, Ronald D. Perrone, Yves Pirson, Robert W. Schrier, Roser Torra, Vicente E. Torres, Terry Watnick, David C. Wheeler, Curie Ahn, Ahsan Alam, Beatrice Aussilhou, Kyongtae T. BaeWilliam M. Bennett, Carsten Bergmann, Daniel G. Bichet, Klemens Budde, Dominique Chauveau, Benjamin Cowley, Brenda De Coninck, Katherine M. Dell, Joost P.H. Drenth, Tevfik Ecder, Francesco Emma, Claude Férec, Bruno Flamion, Flavia Galletti, Bernice Gitomer, Jared J. Grantham, Nicole Harr, Peter C. Harris, Eiji Higashihara, Eiko Hodouchi, Marie C. Hogan, Vivek Jha, Uwe Korst, Corinne Lagrafeuil, Rodolfo S. Martin, Changlin Mei, Michal Mrug, Gregorio T. Obrador, Albert C.M. Ong, Luiz F. Onuchic, Luisa Sternfeld Pavia, Gopala K. Rangan, Richard Sandford, Andreas L. Serra, Theodore I. Steinman, Svend Strandgaard, Gerd Walz, Christopher G. Winearls, Kaori Yamane Winston

Research output: Contribution to journalArticlepeer-review

421 Scopus citations


Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals and is the fourth most common cause for renal replacement therapy worldwide. There have been many recent advances in the understanding of its molecular genetics and biology, and in the diagnosis and management of its manifestations. Yet, diagnosis, evaluation, prevention, and treatment vary widely and there are no broadly accepted practice guidelines. Barriers to translation of basic science breakthroughs to clinical care exist, with considerable heterogeneity across countries. The Kidney Disease: Improving Global Outcomes Controversies Conference on ADPKD brought together a panel of multidisciplinary clinical expertise and engaged patients to identify areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support. These are summarized in this review.

Original languageEnglish (US)
Pages (from-to)17-27
Number of pages11
JournalKidney international
Issue number1
StatePublished - Jul 2 2015

Bibliographical note

Publisher Copyright:
© 2015 International Society of Nephrology.


  • Diagnosis
  • End-stage renal disease
  • Management
  • Patient support
  • Polycystic kidney disease


Dive into the research topics of 'Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference'. Together they form a unique fingerprint.

Cite this